Læknaneminn - 01.04.2020, Blaðsíða 21

R
it
rý
n
t
e
fn
i
R
itr
ýn
t e
fn
i
2
1
KALMENTE NEFÚÐI VIÐ OFNÆMISKVEFI
Kalmente 50 µg/skammt, nefúði, dreifa. 140 skammtar í úðaglasi. Virkt efni: mómetasonfúróat. Ábending: Kalmente
er notað við einkennum ofnæmiskvefs (einnig kallað árstíðabundið ofnæmiskvef) og stöðugs ofnæmiskvefs hjá
18 ára og eldri. Lesið vandlega upplýsingar á umbúðum og fylgiseðli fyrir notkun lyfsins. Leitið til læknis eða
lyfjafræðings sé þörf á frekari upplýsingum um áhættu og aukaverkanir. Sjá nánari upplýsingar um lyfið á
www.serlyfjaskra.is.
alvogen.isK A L . L . A . 2 0 2 0 . 0 0 0 1 . 0 1
FÆST ÁN LYFSEÐILS Í NÆSTA APÓTEKI | LESIÐ FYLGISEÐILINN FYRIR NOTKUN
INNIHELDUR MÓMETASONFÚRÓAT
NÓG EINU SINNI Á SÓLARHRING
NEFÚÐI
140 SKAMMTAR
27. Greil GF, Stuber M, Botnar RM, Kissinger KV, Geva T, Newburger JW,
et al. Coronary magnetic resonance angiography in adolescents and young
adults with kawasaki disease. Circulation. 2002;105(8):908-11.
28. Gurofsky RC, Sabharwal T, Manlhiot C, Redington AN, Benson
LN, Chahal N, et al. Arterial complications associated with cardiac
catheterization in pediatric patients with a previous history of
kawasaki disease. Catheterization and Cardiovascular Interventions.
2009;73(6):809-13.
29. de Graeff N, Groot N, Ozen S, Eleftheriou D, Avcin T, Bader-Meunier
B, et al. European consensus-based recommendations for the diagnosis
and treatment of Kawasaki disease–the SHARE initiative. Rheumatology.
2019;58(4):672-82.
30. Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy
CE, et al. The treatment of Kawasaki syndrome with intravenous gamma
globulin. N Engl J Med. 1986;315(6):341-7.
31. Furusho K, Nakano H, Shinomiya K, Tamura T, Manabe Y, Kawarano M,
et al. HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN FOR
KAWASAKI DISEASE. The Lancet. 1984;324(8411):1055-8.
32. Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ,
et al. A single intravenous infusion of gamma globulin as compared with
four infusions in the treatment of acute Kawasaki syndrome. N Engl J
Med. 1991;324(23):1633-9.
33. Burns JC, Franco A. The immunomodulatory effects of intravenous
immunoglobulin therapy in Kawasaki disease. Expert Rev Clin Immunol.
2015;11(7):819-25.
34. Lee JH, Hung HY, Huang FY. Kawasaki disease with Reye syndrome:
report of one case. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi.
1992;33(1):67-71.
35. Baumer JH, Love S, Gupta A, Haines L, Maconochie IK, Dua JS.
Salicylate for the treatment of Kawasaki disease in children. Cochrane
Database of Systematic Reviews. 2006(4).
36. Wei CM, Chen HL, Lee PI, Chen CM, Ma CY, Hwu WL. Reye’s
syndrome developing in an infant on treatment of Kawasaki syndrome. J
Paediatr Child Health. 2005;41(5-6):303-4.
37. Sakulchit T, Benseler SM, Goldman RD. Acetylsalicylic acid for children
with Kawasaki disease. Can Fam Physician. 632017. p. 607-9.
38. Terai M, Shulman ST. Prevalence of coronary artery abnormalities in
Kawasaki disease is highly dependent on gamma globulin dose but
independent of salicylate dose. J Pediatr. 1997;131(6):888-93.
39. Dhanrajani A, Chan M, Pau S, Ellsworth J, Petty R, Guzman J. Aspirin
Dose in Kawasaki Disease: The Ongoing Battle. Arthritis Care &
Research. 2018;70(10):1536-40.
40. Shendre A, Wiener HW, Zhi D, Vazquez AI, Portman MA, Shrestha S.
High-density genotyping of immune loci in Kawasaki disease and IVIG
treatment response in European-American case–parent trio study. Genes
& Immunity. 2014;15(8):534-42.